Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia

被引：15

作者：

Nabhan, C ^{[1
]}

Rosen, ST ^{[1
]}

机构：

[1] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Chicago, IL 60611 USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 01期

关键词：

D O I：

10.1053/sonc.2002.30150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：75 / 80

页数：6

共 39 条

[1] EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].

ANDERSON, KC ;

BATES, MP ;

SLAUGHENHOUPT, BL ;

PINKUS, GS ;

SCHLOSSMAN, SF ;

NADLER, LM .

BLOOD, 1984, 63 (06) :1424-1433

[2] Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia [J].

Bowen, AL ;

Zomas, A ;

Emmett, E ;

Matutes, E ;

Dyer, MJS ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (03) :617-619

[3] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[4] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[5] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].

Davis, TA ;

White, CA ;

Grillo-López, AJ ;

Velásquez, WS ;

Link, B ;

Maloney, DG ;

Dillman, RO ;

Williams, ME ;

Mohrbacher, A ;

Weaver, R ;

Dowden, S ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857

[6] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

[7] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs [J].

Demidem, A ;

Lam, T ;

Alas, S ;

Hariharan, K ;

Hanna, N ;

Bonavida, B .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) :177-186

[8]

DYER MJS, 1989, BLOOD, V73, P1431

[9]

GILLEECE MH, 1993, BLOOD, V82, P807

[10] Levels of expression of CD19 and CD20 in chronic B cell leukaemias [J].

Ginaldi, L ;

De Martinis, M ;

Matutes, E ;

Farahat, N ;

Morilla, R ;

Catovsky, D .

JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (05) :364-369

← 1 2 3 4 →